Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Freaks of Nature offers sustainable skincare for outdoor athletes, focusing on performance and eco-consciousness with innovative formulations and packaging.
JPMorgan Chase says profits jumped sharply ias the bank cashed in billions of dollars of its holdings in Visa Inc., also helped by higher interest rates.
Archegos's Bill Hwang turned $10 billion into $160 billion into nothing. Plus: Intuit's layoffs, Elon's travails, Boeing's bad week, Jerome Powell, and mor
Language learning apps surged in 2024, with Babbel offering interactive lessons, vocabulary practice, and grammar exercises for effective language acquisition.
